[{"id":"88d90e77-172d-4510-b158-f4795d53f576","acronym":"CRESCENDO","url":"https://clinicaltrials.gov/study/NCT06072131","created_at":"2023-10-10T15:12:06.102Z","updated_at":"2024-07-02T16:35:00.782Z","phase":"Phase 3","brief_title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","source_id_and_acronym":"NCT06072131 - CRESCENDO","lead_sponsor":"Acrotech Biopharma Inc.","biomarkers":" ALK • TNFRSF8 • UGT1A1","pipe":" | ","alterations":" TNFRSF8 expression • UGT1A1*1*1","tags":["ALK • TNFRSF8 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)"],"overall_status":"Recruiting","enrollment":" Enrollment 504","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2024-05-27"},{"id":"52396473-78ff-4d4d-a535-0eca9ead2687","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598998","created_at":"2021-01-18T17:41:43.962Z","updated_at":"2024-07-02T16:35:16.011Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas","source_id_and_acronym":"NCT03598998","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Folotyn (pralatrexate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 06/29/2024","study_completion_date":" 06/29/2024","last_update_posted":"2024-03-06"},{"id":"6534377c-261b-484f-9214-3050310c7c27","acronym":"","url":"https://clinicaltrials.gov/study/NCT01336933","created_at":"2021-01-18T05:27:06.399Z","updated_at":"2024-07-02T16:35:36.065Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01336933","lead_sponsor":"University of Nebraska","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • vincristine • prednisone • Folotyn (pralatrexate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/06/2011","start_date":" 07/06/2011","primary_txt":" Primary completion: 12/28/2016","primary_completion_date":" 12/28/2016","study_txt":" Completion: 12/28/2016","study_completion_date":" 12/28/2016","last_update_posted":"2023-09-22"},{"id":"621fb80b-96ac-4019-a7af-e5bdf7015741","acronym":"","url":"https://clinicaltrials.gov/study/NCT01118624","created_at":"2021-01-18T04:26:10.126Z","updated_at":"2024-07-02T16:36:51.824Z","phase":"Phase 2","brief_title":"Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer","source_id_and_acronym":"NCT01118624","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 07/01/2012","study_completion_date":" 07/01/2012","last_update_posted":"2020-01-07"},{"id":"3d931a31-b046-492c-8fd8-af76f3577629","acronym":"PROPEL","url":"https://clinicaltrials.gov/study/NCT00364923","created_at":"2021-01-18T01:15:54.958Z","updated_at":"2024-07-02T16:36:52.212Z","phase":"Phase 2","brief_title":"Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT00364923 - PROPEL","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" TCL1A","pipe":"","alterations":" ","tags":["TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 01/01/2009","primary_completion_date":" 01/01/2009","study_txt":" Completion: 02/24/2009","study_completion_date":" 02/24/2009","last_update_posted":"2019-12-19"},{"id":"efb1edfc-7620-4989-847a-c677907cef3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188876","created_at":"2021-01-18T04:45:19.051Z","updated_at":"2024-07-02T16:37:14.660Z","phase":"Phase 1/2","brief_title":"Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01188876","lead_sponsor":"Massachusetts General Hospital","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2018-01-19"},{"id":"d213f303-4daa-4ffe-886c-f96b8e4d3c0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03356678","created_at":"2021-01-18T16:34:12.273Z","updated_at":"2024-07-02T16:37:15.966Z","phase":"","brief_title":"Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03356678","lead_sponsor":"Samsung Medical Center","biomarkers":" ALK • TNFRSF8 • TCL1A","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • TNFRSF8 • TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/23/2016","start_date":" 09/23/2016","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2017-11-29"}]